We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Thermo Fisher Scientific Acquisition Augments Specialty Diagnostics Portfolio

By LabMedica International staff writers
Posted on 08 Sep 2009
Print article
Thermo Fisher Scientific Inc. (Waltham, MA, USA) signed a definitive agreement to acquire B.R.A.H.M.S. AG (Hennigsdorf, Germany) for US$478.8 million. B.R.A.H.M.S. will be integrated into the specialty diagnostics business within Thermo Fisher's analytical technologies segment. The transaction, which is subject to regulatory approvals, is expected to close in late September 2009.

B.R.A.H.M.S. is a provider of specialty in vitro diagnostic (IVD) tests based on biomarkers for sepsis, cardiovascular and pulmonary diseases, intensive care treatments, and prenatal screening. It also offers diagnostic tests and instrumentation for thyroid, prenatal, autoimmune, and oncology screening in both laboratory and point-of-care settings. The company's best-known product is Procalcitonin (PCT), a biomarker for the diagnosis and treatment of sepsis, a condition in which the patient's bloodstream is overwhelmed by bacterial infection.

The PCT test has become the gold standard in Europe for early diagnosis of sepsis, which is critical for patient survival, and the subsequent monitoring of treatment. The European testing model will be replicated in the United States where around 750,000 cases occur each year, one third of which are fatal.

Marijn E. Dekkers, president and CEO of Thermo Fisher Scientific, commented, "B.R.A.H.M.S. assays and instrumentation are a strong complement to our existing products for immunoassay testing, and its robust R&D pipeline creates promising opportunities to commercialize new patented diagnostic tests. In addition, the company gives us a significant reagent manufacturing footprint in Europe, while allowing us to leverage our deep customer access in the U.S. to market innovative new B.R.A.H.M.S. products, such as PCT and others now in development. This acquisition reinforces our strategy of building on our leadership in niche specialty diagnostics markets.”

Thermo Fisher Scientific Inc. supplies and serves hospitals and clinical diagnostic labs, pharmaceutic and biotechnology companies, universities, research institutions and government agencies, as well as environmental and industrial process control settings. The company has two brands, Thermo Scientific and Fisher Scientific. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables, and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies, and services used in healthcare, scientific research, safety, and education.

Related Links:

Thermo Fisher Scientific Inc.
B.R.A.H.M.S. AG


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: The new blood test identifies key biomarkers of osteoarthritis (Photo courtesy of Shutterstock)

Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays

Osteoarthritis (OA) is the most prevalent form of arthritis, impacting millions worldwide and resulting in significant economic and social costs. Although no cure exists currently, the effectiveness of... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.